Diloxanide furoate: Difference between revisions

	WikiDoc Resources for Diloxanide furoate
Articles
Most recent articles on Diloxanide furoate Most cited articles on Diloxanide furoate Review articles on Diloxanide furoate Articles on Diloxanide furoate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Diloxanide furoate Images of Diloxanide furoate Photos of Diloxanide furoate Podcasts & MP3s on Diloxanide furoate Videos on Diloxanide furoate
Evidence Based Medicine
Cochrane Collaboration on Diloxanide furoate Bandolier on Diloxanide furoate TRIP on Diloxanide furoate
Clinical Trials
Ongoing Trials on Diloxanide furoate at Clinical Trials.gov Trial results on Diloxanide furoate Clinical Trials on Diloxanide furoate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Diloxanide furoate NICE Guidance on Diloxanide furoate NHS PRODIGY Guidance FDA on Diloxanide furoate CDC on Diloxanide furoate
Books
Books on Diloxanide furoate
News
Diloxanide furoate in the news Be alerted to news on Diloxanide furoate News trends on Diloxanide furoate
Commentary
Blogs on Diloxanide furoate
Definitions
Definitions of Diloxanide furoate
Patient Resources / Community
Patient resources on Diloxanide furoate Discussion groups on Diloxanide furoate Patient Handouts on Diloxanide furoate Directions to Hospitals Treating Diloxanide furoate Risk calculators and risk factors for Diloxanide furoate
Healthcare Provider Resources
Symptoms of Diloxanide furoate Causes & Risk Factors for Diloxanide furoate Diagnostic studies for Diloxanide furoate Treatment of Diloxanide furoate
Continuing Medical Education (CME)
CME Programs on Diloxanide furoate
International
Diloxanide furoate en Espanol Diloxanide furoate en Francais
Business
Diloxanide furoate in the Marketplace Patents on Diloxanide furoate
Experimental / Informatics
List of terms related to Diloxanide furoate

Diloxanide
Clinical data
Trade names	Furamide
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy; category	No available data;
Routes of; administration	Oral
ATC code	P01AC01 (WHO) ;
Legal status
Legal status	Not approved (US, CA);
Pharmacokinetic data
Bioavailability	90% (diloxanide)
Metabolism	Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation
Elimination half-life	3 hours
Excretion	Renal (90%), fecal (10%)
Identifiers
	IUPAC name 4-[(dichloroacetyl)(methyl)amino]phenyl furan-2-carboxylate;
CAS Number	3736-81-0 ;
PubChem CID	19529;
DrugBank	DB08792 ;
ChemSpider	18400 ;
KEGG	D02480 ;
ChEMBL	ChEMBL1334860 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H11Cl2NO4
Molar mass	328.147 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(Oc1ccc(N(C(=O)C(Cl)Cl)C)cc1)c2occc2;
	InChI InChI=1S/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3 ; Key:BDYYDXJSHYEDGB-UHFFFAOYSA-N ;
(what is this?) (verify)

VisualWikitext

Revision as of 13:02, 23 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Diloxanide furoate is a luminal amebicide used in the treatment of Amebiasis.^[1] It is considered the luminal agent of choice for mild intestinal amebiasis or asymptomatic cyst carriers.It can also be added to metronidazole(active drug in luminal and extraintestinal amebiasis) in acute amebic dysentery as well as hepatic abscess(In hepatic abscess it is for the control of cysts in the lumen which may cause relapse). The drug was discovered by The Boots Company Plc in 1956 and introduced as Furamide. The Furamide brand is now owned by Abbott Laboratories. It is not available in the US. In India it is available as Amicline by Franco-Indian.

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.^[2]

Safety and effectiveness

A 13-year study conducted by the United States Center for Disease Control between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of Entamoeba histolytica. ^[3]

References

↑ Fernandes H, D'Souza CR, Swethadri GK, Naik CN (2009). "Ameboma of the colon with amebic liver abscess mimicking metastatic colon cancer". Indian J Pathol Microbiol. 52 (2): 228–30. doi:10.4103/0377-4929.48927. PMID 19332922.
↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
↑ McAuley JB, Herwaldt BL, Stokes SL; et al. (1992). "Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States". Clin. Infect. Dis. 15 (3): 464–8. doi:10.1093/clind/15.3.464. PMID 1520794.

Template:Agents against amoebozoa

Template:Antiinfective-drug-stub

[pmid19332922-1] Fernandes H, D'Souza CR, Swethadri GK, Naik CN (2009). "Ameboma of the colon with amebic liver abscess mimicking metastatic colon cancer". Indian J Pathol Microbiol. 52 (2): 228–30. doi:10.4103/0377-4929.48927. PMID 19332922.

[2] "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

[pmid1520794-3] McAuley JB, Herwaldt BL, Stokes SL; et al. (1992). "Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States". Clin. Infect. Dis. 15 (3): 464–8. doi:10.1093/clind/15.3.464. PMID 1520794.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-__NOTOC__
+{{Drugbox
-{{CMG}}
+| Verifiedfields = changed
+| verifiedrevid = 470454750
+| IUPAC_name = 4-[(dichloroacetyl)(methyl)amino]phenyl furan-2-carboxylate
+| image = Diloxanide furoate.png
+| drug_name = Diloxanide
-==Overview==
+<!--Clinical data-->
+| tradename = Furamide
+| Drugs.com = {{drugs.com|CONS|diloxanide}}
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category = No available data
+| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
+| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
+| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
+| legal_status = Not approved <small>([[United States|US]], [[Canada|CA]])</small>
+| routes_of_administration = Oral
-Diloxanide furoate is an anti-protozoal drug used in the treatment of [[Entamoeba histolytica]] and some other protozoal infections.
+<!--Pharmacokinetic data-->
+| bioavailability = 90% (diloxanide)
+| protein_bound =
+| metabolism = [[hydrolysis|Hydrolyzed]] to furoic acid and diloxanide, which undergoes extensive [[glucuronidation]]
+| elimination_half-life = 3 hours
+| excretion = [[Kidney|Renal]] (90%), fecal (10%)
-==Category==
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|changed|??}}
+| CAS_number = 3736-81-0
+| ATC_prefix = P01
+| ATC_suffix = AC01
+| PubChem = 19529
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank = DB08792
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 18400
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D02480
+| ChEMBL_Ref = {{ebicite|changed|EBI}}
+| ChEMBL = 1334860
-Antiparasitic
+<!--Chemical data-->
+| C=14 | H=11 | Cl=2 | N=1 | O=4
+| molecular_weight = 328.147 g/mol
+| smiles = O=C(Oc1ccc(N(C(=O)C(Cl)Cl)C)cc1)c2occc2
+| InChI = 1/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3
+| InChIKey = BDYYDXJSHYEDGB-UHFFFAOYAB
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = BDYYDXJSHYEDGB-UHFFFAOYSA-N
+}}
-==US Brand Names==
+__NOTOC__
-ENTAMIDE, FUMARIDE (not available in the U.S.)
+{{SI}}
-==Prescribing Information==
+{{CMG}}
-===Therapeutic indications===
+==Overview==
+'''Diloxanide furoate''' is a luminal amebicide used in the treatment of ''[[Amebiasis]].''<ref name="pmid19332922">{{cite journal |author=Fernandes H, D'Souza CR, Swethadri GK, Naik CN |title=Ameboma of the colon with amebic liver abscess mimicking metastatic colon cancer |journal=Indian J Pathol Microbiol |volume=52 |issue=2 |pages=228–30 |year=2009 |pmid=19332922 |doi= 10.4103/0377-4929.48927|url=http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2009;volume=52;issue=2;spage=228;epage=230;aulast=Fernandes}}</ref> It is considered the luminal agent of choice for mild intestinal amebiasis or asymptomatic cyst carriers.It can also be added to metronidazole(active drug in luminal and extraintestinal amebiasis) in acute amebic dysentery as well as hepatic abscess(In hepatic abscess it is for the control of cysts in the lumen which may cause relapse). The drug was discovered by ''The Boots Company Plc'' in 1956 and introduced as ''Furamide''. The ''Furamide'' brand is now owned by [[Abbott Laboratories]]. It is not available in the US. In India it is available as ''Amicline'' by ''Franco-Indian''.
-For the treatment of acute and chronic intestinal [[amebiasis]].
-===Administration===
-Adults: One tablet three times daily for ten days.
-Children: 20 mg/kg bodyweight daily in divided doses for ten days. Furamide is not suitable for use in children weighing less than 25 kg.
-Elderly: There is no need for dosage reduction in the elderly.
-If required, a second course of treatment may be prescribed.
-===Contraindications===
-[[Hypersensitivity]] to diloxanide furoate.
-===Precautions===
-Keep all medicines out of the reach of children.
+<!-- Society and culture -->
+It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].<ref>{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}</ref>
-===Drug Interactions===
+==Safety and effectiveness==
+A 13-year study conducted by the United States [[Center for Disease Control]] between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of ''[[Entamoeba histolytica]].''  <ref name="pmid1520794">{{cite journal |author=McAuley JB, Herwaldt BL, Stokes SL, ''et al.'' |title=Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States |journal=Clin. Infect. Dis. |volume=15 |issue=3 |pages=464–8 |year=1992 |pmid=1520794 |doi=10.1093/clind/15.3.464}}</ref>
-No clinically-significant drug interactions known.
-===Pregnancy and Lactation===
-The safety of Furamide during pregnancy and lactation has not been established and use during these periods should therefore be avoided.
-===Adverse Effects===
-No serious side effects have been reported and the bacterial flora of the gut is not upset. Flatulence sometimes occurs but may usually be disregarded. Occasionally, vomiting, pruritus and urticaria may occur.
-===Overdosage===
-Furamide tablets are unlikely to constitute a hazard in overdosage. In severe overdosage, early gastric lavage is recommended. There is no specific antidote. Treatment should be symptomatic and supportive.
-===Clinical Pharmacology===
-In the gut, diloxanide furoate is largely, if not wholly, hydrolysed into diloxanide and furoic acid under the combined action of bacterial and gut esterases. After absorption, diloxanide is very rapidly conjugated to form a glucuronide. In circulating blood, it is present to about 99% as a glucuronide and 1% as free diloxanide. Diloxanide is predominantly excreted in the urine. It is believed that the unabsorbed diloxanide is the active anti-amoebic substance, up to 10% remaining in the gut which is subsequently excreted as diloxanide in the faeces.
-===Mode of Action===
-Diloxanide furoate is a luminal amoebicide acting principally in the bowel lumen, although its mode of action is not known.<ref>{{Cite web  | last =  | first =  | title = http://www.medicines.org.uk/emc/medicine/10787/SPC | url = http://www.medicines.org.uk/emc/medicine/10787/SPC | publisher =  | date =  | accessdate = }}</ref>
-===Safety and Effectiveness===
-A 13-year study conducted by the United States [[Center for Disease Control]] between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of ''[[Entamoeba histolytica]].''  <ref name="pmid1520794">{{cite journal |author=McAuley JB, Herwaldt BL, Stokes SL, ''et al'' |title=Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States |journal=Clin. Infect. Dis. |volume=15 |issue=3 |pages=464–8 |year=1992 |pmid=1520794 |doi=}}</ref>
-===Availability===
-A [[CDC]] study authorized the use of this drug in the treatment of 4,371 cases of ''[[Entamoeba histolytica]]'' from 1977 to 1990.  <ref name="pmid1520794" />
 ==References==
 {{Reflist|2}}
+{{Agents against amoebozoa}}
+{{antiinfective-drug-stub}}
-[[Category:Antibiotics]]
+[[Category:Antiprotozoal agents]]
-[[Category:Wikinfect]]
+[[Category:Drug]]

Diloxanide furoate: Difference between revisions

Revision as of 13:02, 23 April 2015

Overview

Safety and effectiveness

References

Navigation menu